Evidence map›Paper›PMID 30662332›Full record

ArticleInternational journal of medical sciences2019

Proteomic Study of a Parkinson's Disease Model of Undifferentiated SH-SY5Y Cells Induced by a Proteasome Inhibitor.

Huiyi Jiang, Yang Yu, Shicheng Liu, Mingqin Zhu, Xiang Dong, Jinying Wu, Zhou Zhang, Ming Zhang, Ying Zhang

Open access · goldAbstract read
In one paragraph

Article in International journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Multi-omic network inference from time-series data.NPJ systems biology and applications · 2025
    Article
  2. Article
  3. Article
  4. Identification of Ubiquitination-Associated Proteins Using 2D-DIGE.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Huiyi JiangDepartment of pediatrics, First Hospital of Jilin University, Changchun, Jilin Province, China.
Yang YuDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Chang Chun, Jilin Province, China.
Shicheng LiuDepartment of pediatrics, First Hospital of Jilin University, Changchun, Jilin Province, China.
Mingqin ZhuDepartments of Neurology and Neuroscience Center, First Hospital of Jilin University, Changchun, Jilin Province, China.
Xiang DongKey Laboratory of Medical Cell Biology, Institute of Translational Medicine, China Medical University, Shenyang, Liaoning Province, China.
Jinying WuKey Laboratory of Medical Cell Biology, Institute of Translational Medicine, China Medical University, Shenyang, Liaoning Province, China.
Zhou ZhangKey Laboratory of Medical Cell Biology, Institute of Translational Medicine, China Medical University, Shenyang, Liaoning Province, China.
Ming ZhangDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Chang Chun, Jilin Province, China.
Ying ZhangDepartments of Neurology and Neuroscience Center, First Hospital of Jilin University, Changchun, Jilin Province, China.
China Medical University · CNJilin University · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is one of the most common nervous system degenerative diseases. However, the etiology of this disease remains elusive. Here, a proteasome inhibitor (PSI)-induced undifferentiated SH-SY5Y PD model was established to analyze protein alterations through proteomic study.

methodsCultured undifferentiated SH-SY5Y cells were divided into a control group and a group treated with 2.5 µM PSI (PSI-treated group). An methyl thiazolyl tetrazolium (MTT) assay was applied to detect cell viability. Acridine orange/ethidium bromide (AO/EB), α-synuclein immunofluorescence and hematoxylin and eosin (H&E) staining were applied to evaluate apoptosis and cytoplasmic inclusions, respectively. The protein spots that were significantly changed were separated, analyzed by 2D gel electrophoresis and DIGE De Cyder software, and subsequently identified by MALDI-TOF mass spectrometry and database searching.

resultsThe results of the MTT assay showed that there was a time and dose dependent change in cell viability following incubation with PSI. After 24 h incubation, PSI resulted in early apoptosis, and cytoplasmic inclusions were found in the PSI-treated group through H&E staining and α-synuclein immunofluorescence. Thus, undifferentiated SH-SY5Y cells could be used as PD model following PSI-induced inhibition of proteasomal function. In total, 18 proteins were differentially expressed between the groups, 7 of which were up-regulated and 11 of which were down-regulated. Among them, 5 protein spots were identified as being involved in the ubiquitin proteasome pathway-induced PD process.

conclusionsMitochondrial heat shock protein 75 (MTHSP75), phosphoglycerate dehydrogenase (PHGDH), laminin binding protein (LBP), tyrosine 3/tryptophan 5-monooxygenase activation protein (14-3-3ε) and YWHAZ protein (14-3-3ζ) are involved in mitochondrial dysfunction, serine synthesis, amyloid clearance, apoptosis process and neuroprotection. These findings may provide new clues to deepen our understanding of PD pathogenesis.

Indexed as

Proteomics14-3-3 ProteinsApoptosisCarrier ProteinsCell Line, TumorCell SurvivalDown-RegulationHeat-Shock ProteinsHumansInclusion BodiesLamininParkinson DiseaseParkinson Disease, SecondaryPhosphoglycerate DehydrogenaseProteasome Endopeptidase ComplexProteasome Inhibitors14-3-3 ProteinsCarrier ProteinsHeat-Shock ProteinsLamininPhosphoglycerate DehydrogenaseProteasome Endopeptidase ComplexProteasome InhibitorsUbiquitinParkinson's diseaseproteomicsptoteasomes inhibitorSH-SY5Y cellsubiquitin proteasome system

Identifiers

PMID30662332
PMCPMC6332475
OpenAlexW2904038656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.